ArticleBlood advances2026

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

Joseph Kauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.